Phio Pharmaceuticals to present at Renmark virtual non-deal roadshow, host live Q&A

Phio Pharmaceuticals

Phio Pharmaceuticals

PHIO

0.00
  • Phio Pharmaceuticals will present at Renmark Financial Communications’ live virtual non-deal roadshow on May 28, 2026 at 12 p.m. EDT.
  • CEO Robert Bitterman is slated to outline the INTASYL siRNA platform, including lead clinical candidate PH-762 in cutaneous carcinomas.
  • A live Q&A session is scheduled to follow the presentation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202605260700NEWSFILECNPR____20260526_298745_1) on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.